Bristol Myers Squibb Company (BMY) vs Gilead Sciences, Inc. (GILD)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Gilead Sciences, Inc. GILD 156.19 −0.75%
Bristol Myers Squibb Company and Gilead Sciences, Inc. are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $195.1B against $123.7B — 1.6× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Bristol Myers Squibb Company trades at 13.2×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 5.52% against 3.11%. Bristol Myers Squibb Company has the higher net margin (18.9% vs −10.6%) and the higher return on invested capital (13.7% vs −4.48%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.22% vs 2.08%). Across the 22 metrics below, Bristol Myers Squibb Company leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | BMY | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 79.59% | 72.77% |
| Operating margin | 24.22% | (8.20%) | 18.77% |
| Net margin | 18.87% | (10.64%) | 8.27% |
| Free cash flow margin | 23.26% | 42.50% | 17.18% |
| Return on equity | 46.63% | (20.68%) | 5.87% |
| Return on assets | 10.18% | (6.17%) | 2.57% |
| Return on invested capital | 13.69% | (4.48%) | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack